Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Socioeconomic Context and Brain Ageing in Epilepsy: an ENIGMA-Epilepsy study.

medRxiv : the preprint server for health sciences·2026
Same author

Species-level virome profiling reveals compositional differences in the gut prokaryotic DNA virome of people with HIV-1 on antiretroviral therapy.

Gut microbes reports·2026
Same author

Letter to the editor: When do rare events become expected in HIV drug resistance?

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

Open forum infectious diseases·2026
Same author

Increased in-hospital mortality in immunocompromised individuals hospitalized with COVID-19 during the global pandemic, a multinational cohort study in the EuCARE project.

The Journal of infectious diseases·2026
Same author

HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.

HIV medicine·2026

Related Experiment Video

Updated: May 30, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

HIV-1 mutational pathways under multidrug therapy.

Glenn Lawyer1, André Altmann, Alexander Thielen

  • 1Department of Computational Biology, Max Planck Institute for Informatics, Saarbrücken, Germany. lawyer@mpi-inf.mpg.de.

AIDS Research and Therapy
|July 29, 2011
PubMed
Summary
This summary is machine-generated.

Understanding HIV-1 mutational pathways is key for effective therapy. Previous treatments significantly impact nucleoside reverse transcriptase inhibitor (NRTI) resistance, more than existing mutations.

More Related Videos

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Related Experiment Videos

Last Updated: May 30, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
10:18

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

Published on: October 16, 2018

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Area of Science:

  • Virology
  • Genetics
  • Pharmacology

Background:

  • Genotype-derived drug resistance profiles aid HIV-1 therapy decisions.
  • Knowledge of viral mutational pathways can improve prediction of therapy success and preserve future options.
  • This study focuses on HIV-1 reverse transcriptase mutations affecting nucleoside (NRTI) and non-nucleoside (NNRTI) reverse transcriptase inhibitors.

Purpose of the Study:

  • To identify specific HIV-1 mutational pathways in the reverse transcriptase region.
  • To determine how preexisting mutations influence the emergence of new resistance mutations.
  • To enhance the prediction of HIV-1 therapy outcomes.

Main Methods:

  • A Cox proportional hazards model was used to analyze mutation pathways.
  • Regularized regression (SCAD) identified important covariates (mutations).
  • Data from 1981 therapies in the EuResist database were analyzed, controlling for non-genetic factors.

Main Results:

  • The number of previous therapies, not existing mutations, was the strongest predictor of NRTI resistance.
  • Confirmed known NRTI resistance pathways and evidenced inhibition between thymidine analog pathways.
  • Identified pathways between NRTI and NNRTI resistance sites, with some mutations increasing the risk for both.

Conclusions:

  • Incorporating the number of previous treatments improves HIV-1 therapy outcome prediction.
  • Considering specific genomic locations that increase resistance mutation risk enhances predictive accuracy.
  • Understanding mutational pathways is crucial for optimizing HIV-1 treatment strategies.